Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
January 27,2010,
Somaxon Pharmaceuticals to Present
at the 12th Annual BIO CEO & Investor Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present a company overview at the 12 th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Monday, February 8th at 9:30 A.M. Eastern Time.
A live webcast of the presentation will be available in the Investor Relations section of the company's Web site under Event Scheduler at www.somaxon.com . The webcast will be archived and accessible for at least 14 days. (.pdf)
January 21, 2010, SOMAXON PROVIDES UPDATE ON NEW DRUG APPLICATION FOR
SILENOR® FOR THE TREATMENT OF INSOMNIA
Resubmission has been filed, with 2 month review cycle
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia. (.pdf)
